Literature DB >> 25083054

Irritable bowel syndrome: a concise review of current treatment concepts.

Geoffrey C Wall1, Ginelle A Bryant1, Michelle M Bottenberg1, Erik D Maki1, Andrew R Miesner1.   

Abstract

Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders causing patients to seek medical treatment. It is relatively resource intensive and the source of significant morbidity. Recent insights into the pathophysiology and treatment of IBS has given clinicians more options than ever to contend with this disorder. The purpose of our paper is to review older, "classic" treatments for IBS as well as newer agents and "alternative" therapies. We discuss the evidence base of these drugs and provide context to help develop appropriate treatment plans for IBS patients.

Entities:  

Keywords:  Irritable bowel syndrome; Linaclotide; Lubiprostone; Peppermint oil; Probiotics; Rifaximin

Mesh：

Substances：

Year:  2014        PMID： 25083054      PMCID： PMC4112883          DOI： 10.3748/wjg.v20.i27.8796

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


  67 in total

Review 1.  Microbiota restoration: natural and supplemented recovery of human microbial communities.

Authors:  Gregor Reid; Jessica A Younes; Henny C Van der Mei; Gregory B Gloor; Rob Knight; Henk J Busscher
Journal:  Nat Rev Microbiol       Date:  2010-11-29       Impact factor: 60.633

Review 2.  Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials.

Authors:  J Jailwala; T F Imperiale; K Kroenke
Journal:  Ann Intern Med       Date:  2000-07-18       Impact factor: 25.391

Review 3.  Altered neuro-endocrine-immune pathways in the irritable bowel syndrome: the top-down and the bottom-up model.

Authors:  Cristina Stasi; Massimo Rosselli; Massimo Bellini; Giacomo Laffi; Stefano Milani
Journal:  J Gastroenterol       Date:  2012-07-06       Impact factor: 7.527

4.  Recommendations for probiotic use-2011 update.

Authors:  Martin H Floch; W Allan Walker; Karen Madsen; Mary Ellen Sanders; George T Macfarlane; Harry J Flint; Levinus A Dieleman; Yehuda Ringel; Stefano Guandalini; Ciaran P Kelly; Lawrence J Brandt
Journal:  J Clin Gastroenterol       Date:  2011-11       Impact factor: 3.062

5.  Irritable Bowel Syndrome: Bacterial Overgrowth--What's Known and What to Do.

Authors:  Mark Pimentel; Sheila Lezcano
Journal:  Curr Treat Options Gastroenterol       Date:  2007-08

Review 6.  Pharmacologic treatment of constipation: what is new?

Authors:  Daniel Pohl; Radu Tutuian; Michael Fried
Journal:  Curr Opin Pharmacol       Date:  2008-08-20       Impact factor: 5.547

7.  Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.

Authors:  Viola Andresen; Michael Camilleri; Irene A Busciglio; April Grudell; Duane Burton; Sanna McKinzie; Amy Foxx-Orenstein; Caroline B Kurtz; Vineeta Sharma; Jeffrey M Johnston; Mark G Currie; Alan R Zinsmeister
Journal:  Gastroenterology       Date:  2007-07-03       Impact factor: 22.682

8.  Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial.

Authors:  G Cappello; M Spezzaferro; L Grossi; L Manzoli; L Marzio
Journal:  Dig Liver Dis       Date:  2007-04-08       Impact factor: 4.088

9.  Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance.

Authors:  J McCarthy; L O'Mahony; L O'Callaghan; B Sheil; E E Vaughan; N Fitzsimons; J Fitzgibbon; G C O'Sullivan; B Kiely; J K Collins; F Shanahan
Journal:  Gut       Date:  2003-07       Impact factor: 23.059

10.  Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome.

Authors:  I M Carroll; T Ringel-Kulka; J P Siddle; Y Ringel
Journal:  Neurogastroenterol Motil       Date:  2012-02-20       Impact factor: 3.598
View more
  14 in total

1.  Rifaximin: irritable bowel syndrome.

Authors:  Joyce A Generali; Dennis J Cada
Journal:  Hosp Pharm       Date:  2014-12

Review 2.  Design and implementation of novel nutraceuticals and derivatives for treating intestinal disorders.

Authors:  Maria J Barahona; Vanessa Baratta; Jenna Ollodart; David Mulligan; John P Geibel
Journal:  Future Med Chem       Date:  2019-04-17       Impact factor: 3.808

3.  Effect of probiotics and dietary fiber combined with pinaverium bromide on intestinal flora in patients with irritable bowel syndrome.

Authors:  Han Sun; Xueting Li; Weixu Chen; Fangyuan Jia; Jing Su; Bao Zhang; Xia Wu; Ping Wu
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

4.  Self-medication of irritable bowel syndrome and dyspepsia: How appropriate is it?

Authors:  Ramin Niknam; Sarah Mousavi; Alireza Safarpour; Laleh Mahmoudi; Paria Mahmoudi
Journal:  J Res Pharm Pract       Date:  2016 Apr-Jun

5.  Irritable bowel syndrome symptom severity improves equally with probiotic and placebo.

Authors:  Anna Lyra; Markku Hillilä; Teppo Huttunen; Sofia Männikkö; Mikko Taalikka; Julia Tennilä; Anneli Tarpila; Sampo Lahtinen; Arthur C Ouwehand; Lea Veijola
Journal:  World J Gastroenterol       Date:  2016-12-28       Impact factor: 5.742

Review 6.  Pharmacological Approach for Managing Pain in Irritable Bowel Syndrome: A Review Article.

Authors:  Longtu Chen; Sheikh J Ilham; Bin Feng
Journal:  Anesth Pain Med       Date:  2017-01-25

Review 7.  Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic Dichotomy.

Authors:  Uday C Ghoshal; Ratnakar Shukla; Ujjala Ghoshal
Journal:  Gut Liver       Date:  2017-03-15       Impact factor: 4.519

8.  The association of catastrophizing with quality-of-life outcomes in patients with irritable bowel syndrome.

Authors:  LeeAnne B Sherwin; Emily Leary; Wendy A Henderson
Journal:  Qual Life Res       Date:  2017-03-21       Impact factor: 4.147

9.  Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial.

Authors:  Dorte Eskesen; Lillian Jespersen; Birgit Michelsen; Peter J Whorwell; Stefan Müller-Lissner; Cathrine M Morberg
Journal:  Br J Nutr       Date:  2015-09-18       Impact factor: 3.718

10.  Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome.

Authors:  Natalia Zeber-Lubecka; Maria Kulecka; Filip Ambrozkiewicz; Agnieszka Paziewska; Krzysztof Goryca; Jakub Karczmarski; Tymon Rubel; Wojciech Wojtowicz; Piotr Mlynarz; Lukasz Marczak; Roman Tomecki; Michal Mikula; Jerzy Ostrowski
Journal:  Gut Microbes       Date:  2016-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.